Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Retained Earnings: 2009-2025

Historic Retained Earnings for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $8.2 billion.

  • UNITED THERAPEUTICS's Retained Earnings rose 18.37% to $8.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 billion, marking a year-over-year increase of 18.37%. This contributed to the annual value of $7.2 billion for FY2024, which is 19.83% up from last year.
  • According to the latest figures from Q3 2025, UNITED THERAPEUTICS's Retained Earnings is $8.2 billion, which was up 4.31% from $7.9 billion recorded in Q2 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's Retained Earnings peaked at $8.2 billion during Q3 2025, and registered a low of $3.9 billion during Q1 2021.
  • Its 3-year average for Retained Earnings is $6.7 billion, with a median of $6.6 billion in 2024.
  • Data for UNITED THERAPEUTICS's Retained Earnings shows a peak YoY increased of 19.88% (in 2024) over the last 5 years.
  • Over the past 5 years, UNITED THERAPEUTICS's Retained Earnings (Quarterly) stood at $4.3 billion in 2021, then rose by 16.86% to $5.0 billion in 2022, then climbed by 19.53% to $6.0 billion in 2023, then increased by 19.83% to $7.2 billion in 2024, then grew by 18.37% to $8.2 billion in 2025.
  • Its Retained Earnings stands at $8.2 billion for Q3 2025, versus $7.9 billion for Q2 2025 and $7.5 billion for Q1 2025.